STOCK TITAN

Neogenomics Inc. - NEO STOCK NEWS

Welcome to our dedicated news page for Neogenomics (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neogenomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neogenomics's position in the market.

Rhea-AI Summary
NeoGenomics, Inc. (NEO) presents key findings from 11 abstracts at the AACR 2024 Annual Meeting, showcasing its commitment to advancing cancer patient care through innovative research. The company's comprehensive approach covers tumor microenvironment, liquid biopsy assays, genetic alterations identification, and more, emphasizing collaboration for cancer care advancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary
NeoGenomics, Inc. (NEO) released its 2023 Environmental, Social, and Governance (ESG) Report, showcasing progress in sustainability, diversity, and customer experience. The report emphasizes key areas like diversity, environmental stewardship, corporate governance, and employee engagement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.57%
Tags
none
-
Rhea-AI Summary
NeoGenomics, Inc. (NEO) to participate in TD Cowen 44th Annual Health Care Conference. Management team to hold fireside chat on March 5th. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
Rhea-AI Summary
NeoGenomics, Inc. (NEO) reported a 12% increase in fourth-quarter revenue to $156 million and a 16% increase in full-year revenue to $592 million in 2023. Despite a 17% decrease in Advanced Diagnostics revenue in the fourth quarter, the company's net loss decreased by 37% in Q4 and 39% for the full year. Adjusted EBITDA showed positive growth, with a $9 million increase in Q4 and a $51 million increase for the full year. The company issued optimistic 2024 financial guidance, expecting a 10-12% revenue increase, a 600-700% increase in Adjusted EBITDA, and a reduction in net loss by 18-25% compared to 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.11%
Tags
earnings
-
Rhea-AI Summary
NeoGenomics, Inc. signs the Working with Cancer Pledge, demonstrating its commitment to supporting team members living with or caring for a loved one with cancer. The company aims to open the conversation around cancer in the workplace and ensure employees are aware of available resources. With 1 in 2 men and 1 in 3 women likely to be diagnosed with cancer in their lifetime, NeoGenomics pledges to provide job security during treatment, access to medical support, clinical trial matching, and testing covered by the insurance provider for employees and their families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ: NEO) will report its Q4 and full year 2023 financial results on February 20, 2024. A webcast and conference call will be held to discuss the results and recent highlights. The live webcast can be accessed on the Investor Relations section of their website. The call can also be accessed via telephone with the provided participant access code.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
conferences earnings
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ: NEO) to present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
-
News
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ:NEO) announces appeal of preliminary injunction related to RaDaR technology patent infringement. Patients and research projects using RaDaR allowed to continue. CEO Chris Smith reaffirms commitment to defending technology and bringing sensitive test to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.1%
Tags
none
-
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ:NEO) will present new data on its RaDaR assay for minimal residual disease (MRD) at the 46th annual San Antonio Breast Cancer Symposium (SABCS). The data will feature an updated analysis of the TRACER study, showcasing the potential utility of RaDaR in early-stage breast cancer, including baseline detection, therapy response monitoring, and post-operative recurrence monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ:NEO) will participate in the Piper Sandler 35th Annual Global Healthcare Conference in New York City. Members of NeoGenomics' management team will engage in a fireside chat on November 29th at 9:00 a.m. Eastern Time. A live and archived audio webcast of the presentation will be accessible on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.71%
Tags
conferences
Neogenomics Inc.

Nasdaq:NEO

NEO Rankings

NEO Stock Data

2.01B
125.96M
1.21%
100.87%
5.71%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Fort Myers

About NEO

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig